Improved Disease-Free Survival With Adjuvant Erlotinib in EGFR-Mutant, Early-Stage NSCLC

Individuals with early-stage EGFR-mutant NSCLC who were administered erlotinib showed improved 2-year DFS compared with genotype-matched historical controls.

from Latest articles from Cancer Therapy Advisor News http://bit.ly/2AXLa6A